...
首页> 外文期刊>Oncology letters >Intensity-modulated radiotherapy combined with iodine-125 seed implantation in non-central recurrence of cervical cancer: A case report and literature review
【24h】

Intensity-modulated radiotherapy combined with iodine-125 seed implantation in non-central recurrence of cervical cancer: A case report and literature review

机译:强度调节放疗联合碘-125种子植入在宫颈癌的非中央复发中:案例报告和文献综述

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Recurrent cervical cancer is a clinically complex disease that is difficult to treat. There are numerous treatment options, but the results achieved by each are poor. External-beam radiation therapy of the pelvic lymph drainage area, in combination with intracavitary after-loading or the interstitial implantation of a radiation source (i.e., brachytherapy), are the current standard radiotherapy regimens used in high-risk clinical targets. However, there are few reports concerning the use of iodine-125 (I-125) seed implantation brachytherapy in recurrent cervical cancer, and the effects of treatment and adverse reactions have not yet been systematically evaluated. In the present study one such case is reported, in which the patient was successfully treated with intensity-modulated radiotherapy (IMRT) in combination with I-125 seed implantation. The patient, a 47-year-old woman, was initially diagnosed with International Federation of Gynecology and Obstetrics stage IB1 cervical cancer, and received a radical hysterectomy, left lateral adnexectomy and pelvic lymph node dissection. A follow-up examination 23 months later revealed vaginal invasion and a solitary lump in the cervical stump with a maximum diameter of 38 mm. The patient was subsequently diagnosed with recurrent cervical cancer and was treated with six cycles of docetaxel and nedaplatin chemotherapy, alongside IMRT and interstitial I-125 seed implantation. At the point of manuscript submission, the patient's progression-free survival time was 33 months and long-term adverse reactions were acceptable. The response of this patient indicates that I-125 seed implantation could be used as a complementary treatment for recurrent cervical cancer and may also prove to be a reliable means for the comprehensive treatment of primary cervical cancer, as the patient had characteristics similar to primary cervical cancer, although this hypothesis could not be confirmed in the present study.
机译:复发性宫颈癌是一种临床复杂的疾病,难以治疗。有许多治疗方案,但每个治疗结果都是穷人。盆腔淋巴引流区域的外束辐射治疗与腔内后加载或辐射源(即,近距离放射治疗)的间隙植入,是高危临床靶标中使用的目前的标准放射治疗方案。然而,含有碘-125(I-125)种子植入近距离放射治疗的报告少数关于复发性宫颈癌,并且尚未系统地评估治疗和不良反应的影响。在本研究中,报告了一种这种情况,其中患者用强度调节的放射治疗(IMRT)与I-125种子植入组合成功处理。患者是一名47岁的女性,最初被诊断出患有国际妇科和妇产科IB1宫颈癌联合会,并接受了一种激进的子宫切除术,左侧侧髁切除术和盆腔淋巴结解剖。后续检查23个月后显示阴道入侵和颈部垂直肿块,最大直径为38毫米。随后患者被诊断出患有复发性宫颈癌,并用六个循环的多西紫杉醇和Nedaplatin化疗治疗,以及IMRT和间质I-125种子植入。在手稿提交的地步,患者的无进展生存时间为33个月,可接受长期不良反应。该患者的响应表明,I-125种子植入可以用作复发性宫颈癌的互补治疗,并且由于患者具有类似于原代颈椎的特征,因此还可以证明是综合治疗原发性宫颈癌的可靠手段。癌症,虽然在本研究中无法确认这种假设。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号